Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease

Journal of Neuroinflammation

Volumn 3, Issue , 2006, Pages

  Vijitruth, Rattanavijit ^a   Liu, Mei ^a   Choi, Dong Young ^a   Nguyen, Xuan V ^a   Hunter, Randy L ^a   Bing, Guoying ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLOOXYGENASE 2; TYROSINE 3 MONOOXYGENASE; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL LOSS; CONTROLLED STUDY; COORDINATION DISORDER; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MICROGLIA; MOUSE; MOUSE STRAIN; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PATHOGENESIS; ROTAROD TEST; SUBSTANTIA NIGRA;

EID: 33645867671     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-3-6     Document Type: Article

References (53)

1. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. PNAS 2003, 100:5473-5478.
2. McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
3. Samuelsson B: Arachidonic acid metabolism: role in inflammation. Z Rheumatol 1991, 50 Suppl 1:3-6.
4. Wenzel SE: Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997, 17:3S-12S.
5. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266:12866-12872.
6. Needleman P, Isakson PC: The discovery and function of COX-2. J Rheumatol 1997, 24 Suppl 49:6-8.
7. Nikolic D, van Breemen RB: DNA oxidation induced by cyclooxygenase-2. Chem Res Toxicol 2001, 14:351-354.
8. Nakamura Y: Regulating factors for microglial activation. Biol Pharm Bull 2002, 25:945-953.
9. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano GB: Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit 2002, 8:RA165-77.
10. Arimoto T, Bing G: Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 2003, 12:35-45.
11. Liu B, Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7.
12. Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S: COX-2 and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci 2003, 991:272-277.
13. Minghetti L: Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63:901-910.
14. Minghetti L, Levi G: Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998, 54:99-125.
15. Teismann P, Tieu K, Cohen O, Choi DK, Wu du C, Marks D, Vila M, Jackson-Lewis V, Przedborski S: Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003, 18:121-129.
16. Gebicke-Haerter PJ: Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 2001, 54:47-58.
17. Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, Wilson B, Reece JM, Miller DS, Hong JS: MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. Faseb J 2005, 19:1134-1136.
18. Etminan M, Gill S, Samii A: Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Bmj 2003, 327:128.
19. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003, 60:1059-1064.
20. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, et al.: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83:473-482.
21. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN: Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002, 22:2246-2254.
22. West MJ: New stereologicall methods for counting neurons. Neurobiol Aging 1993, 14:275-285.
23. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL: The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 1998, 83:165-175.
24. Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 2001, 15:2057-2072.
25. Langenbach ROBERT, LOFTIN CHARLESD, LEE CHRISTOPHER, TIANO HOWARD: Cyclooxygenase-deficient Mice: A Summary of Their Characteristics and Susceptibilities to Inflammation and Carcinogenesis. Ann NY Acad Sci 1999, 889:52-61.
26. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH: Age-related microglial activation in 1-methyl -4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003, 964:288-294.
27. Teismann P, Ferger B: Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39:167-174.
28. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, Hong JS: Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyll, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neuroscience Letters 2002, 329:354-358.
29. Koutsilieri E, Scheller C, Tribl F, Riederer P: Degeneration of neuronal cells due to oxidative stress-microglial contribution. Parkinsonism Relat Disord 2002, 8:401-406.
30. Hartmann A, Hunot S, Hirsch EC: Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp Neurol 2003, 184:561-564.
31. Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O: Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 2004, 1:6.
32. Isacson O, Brundin P, Gage FH, Bjorklund A: Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 1985, 16:799-817.
33. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, Hirsch EC, Herrero MT: Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004, 46:402-409.
34. McGeer PL, Schwab C, Parent A, Doudet D: Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003, 54:599-604.
35. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
36. Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH: The protective effects of PBN against MPTP toxicity are independent of hydroxyll radical trapping. Pharmacol Biochem Behav 2000, 65:425-431.
37. Ferger B, Spratt C, Teismann P, Seitz G, Kuschinsky K: Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 1998, 360:155-163.
38. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K: Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol 1998, 358:351-359.
39. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y: Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999, 147:90-95.
40. Ricaurte GA, Irwin I, Forno LS, DeLanney LE, Langston E, Langston JW: Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 1987, 403:43-51.
41. Sugama S, Cho BP, Degiorgio LA, Shimizu Y, Kim SS, Kim YS, Shin DH, Volpe BT, Reis DJ, Cho S, Joh TH: Temporal and sequential analysis of microglia in the substantia nigra following medial forebrain bundle axotomy in rat. Neuroscience 2003, 116:925-933.
42. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC: FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in gliall cells. J Neurosci 1999, 19:3440-3447.
43. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS, Jeng KC: Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002, 16:2103-2112.
44. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B: Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002, 81:1285-1297.
45. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994, 172:151-154.
46. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R, Suzumura A: Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 2005, 280:10444-10454.
47. Schiefer J, Kampe K, Dodt HU, Zieglgansberger W, Kreutzberg GW: Microglial motility in the rat facial nucleus following peripheral axotomy. J Neurocytol 1999, 28:439-453.
48. Volpe BT, Wildmann J, Altar CA: Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience 1998, 83:741-748.
49. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, Levi G: Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1997, 19:152-160.
50. Stokes AH, Hastings TG, Vrana KE: Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55:659-665.
51. Hastings TG: Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995, 64:919-924.
52. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
53. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP: Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 2003, 966:245-252.